Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formaat: | Revisão |
Taal: | Engels |
Gepubliceerd in: |
2023
|
Online toegang: | https://doi.org/10.1002/art.42538 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|